Get it on Google Play

Palisade Bio doses first patient in Phase 2b ulcerative colitis trial

October 28, 2026 8:32 AM EDT Send to a Friend
Palisade Bio, Inc. (Nasdaq: PALI) announced that the first patient has been dosed in ASCENTRA-UC, its global Phase 2b clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login